Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.

Pharmaceutical

Azura Ophthalmics

Marc Gleeson

Helga Mikkelsen

Guy Katsav

Patty Delaney

Omer Rafaeli

Ashwin Agarwal

Hila Barash

Yair Alster

Shimon Nahum

Charles Bosworth

Abby Aharonov

Leadership Team

Advisory Team

Research and Development Team

Teams at Azura Ophthalmics

Leadership Team

Advisory Team

Research and Development Team